October 16, 2026- To help close the knowledge gaps for people living with inflammatory bowel disease (IBD) like Crohn’s disease and ulcerative colitis, Cardinal Health Real-World Data and Evidence, in collaboration with Eli Lilly and Company (“Lilly”) has launched a study called INSIGHT-IBD leveraging its Specialty Networks Research Network of community gastroenterology practices. This real-world evidence study will leverage first-party electronic health records, prospective data collection and patient surveys to capture a long-term picture of what IBD patient care looks like outside of a clinical trial.
Millions of people around the globe live with inflammatory bowel disease (IBD) like Crohn’s disease and ulcerative colitis. These chronic conditions cause inflammation of the gastrointestinal tract that severely impacts quality of life, productivity and long-term health. Though treatments exist, doctors and researchers still lack a clear picture of how they perform for patients outside of a controlled clinical trial environment and in everyday settings. They don’t know how well the treatments control symptoms over time, how long patients stay on their prescribed therapies, why they switch treatments or how these choices ultimately impact hospitalizations, emergency visits and healthcare costs.
INSIGHT-IBD is designed to compare outcomes between patients receiving mirikizumab (Omvoh®), an approved biologic therapy from Lilly that blocks a key protein causing chronic inflammation, and patients who receive other biologic therapies chosen by their physicians.